Paper Details

  1. Home
  2. Paper Details

Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly.

Author: AsaokaNaoko, FujitaKazue, HondaNobuhiro, KuriharaTakeyuki, NakamuraJunichi, OhbaHideo, OkimotoNiro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Sulbactam/ampicillin is effective for community-acquired bacterial pneumonia in elderly patients with a good safety profile.
Paper Details　
Original Abstract of the Article :
Sulbactam/ampicillin (SBT/ABPC) was administered to 83 patients aged over 75 years with community-acquired bacterial pneumonia (mild, n = 43; moderate, n = 40), and its clinical effect was reviewed. It was effective in 37 of the 43 patients with mild disease (efficacy rate, 86.0%), in 27 of the 40 p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12825120

データ提供：米国国立医学図書館（NLM）

Sulbactam/Ampicillin: A Potential Oasis for Elderly Patients with Pneumonia

Pneumonia, a formidable foe that can strike anyone, especially the elderly, is a constant threat to health. This study explores the efficacy and safety of sulbactam/ampicillin (SBT/ABPC) in treating community-acquired pneumonia in elderly patients. The researchers, like intrepid explorers navigating a desert of health challenges, analyze the clinical effects of SBT/ABPC in a group of 83 patients aged over 75 years, seeking to provide a valuable guide for treating this common infection.

Sulbactam/Ampicillin: A Promising Treatment Option for Elderly Patients with Pneumonia

The study demonstrates the effectiveness of SBT/ABPC in treating community-acquired pneumonia in elderly patients. The results show a significant improvement in clinical outcomes, suggesting that SBT/ABPC may be a valuable treatment option for this vulnerable population. The research offers a ray of hope in the fight against pneumonia, a common and often serious ailment.

Ensuring Safe and Effective Treatment for Elderly Patients with Pneumonia

The study emphasizes the importance of carefully monitoring patients for potential side effects while treating pneumonia. By adhering to appropriate protocols and closely observing patients, healthcare providers can ensure the safe and effective use of SBT/ABPC, promoting positive treatment outcomes for elderly patients battling this challenging infection.

Dr. Camel's Conclusion

This study, a beacon of hope in the desert of pneumonia research, highlights the potential of sulbactam/ampicillin as a valuable treatment option for elderly patients. By carefully monitoring for side effects and implementing appropriate protocols, healthcare providers can effectively manage this common and potentially serious infection, promoting the health and well-being of this vulnerable population.

Date :
  1. Date Completed 2003-10-10
  2. Date Revised 2018-05-09
Further Info :

Pubmed ID

12825120

DOI: Digital Object Identifier

S1341-321X(04)71152-6

Related Literature

Article Analysis
・Side Effects of ampicillin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.